Ask AI
ProCE Banner Events

Share

Improving Outcomes for Patients With NSCLC Through the Optimal Integration of HER2-Targeted Antibody‒Drug Conjugate Therapy

Join us to learn more about how to optimally integrate HER2-targeted antibody‒drug conjugate therapy for your patients with NSCLC. During this live meeting, you will have the opportunity to interact with an expert and ask questions at the end of the session. Register today!

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Registration not open

Who Should Attend

This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals caring for patients with NSCLC.

Time and location

Wednesday, November 08, 2023

7:15 AM - 8:15 AM Pacific Time (PT)

Virtual

Private Event | Host Group WA
Spokane, Washington

Agenda

  • Welcome and introduction
  • Case-guided discussions
    • HER2 biology, expression, and background in NSCLC and expert-recommended genomic testing strategies
    • Integration of HER2-targeted ADCs into the NSCLC treatment landscape through expert-guided review of current and emerging clinical data
    • Individualized adverse event identification and management strategies with HER2-targeted ADC therapy
  • Question and answer session

Location

Venue Name

Private Event | Host Group WA

Address

Private Event | Host Group WA
Spokane, Washington

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC). 

Target Audience
This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals caring for patients with NSCLC. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate optimal testing and assessment strategies to identify patients most likely to benefit from HER2-targeted antibody-drug conjugate therapy
  • Develop treatment plans using HER2-directed antibody-drug conjugates considering recent FDA approvals, emerging data and individualized patient characteristics
  • Prepare strategies for effective identification and management of AEs associated with HER2-targeted therapies considering pharmacologic activity, patient history, and disease- versus drug-related symptoms

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-219-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.